Charlotte De Bleye

Dr. Charlotte De Bleye

orcid

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2021 in Journal of Pharmaceutical and Biomedical Analysis
Verified
Journal Article
Closed access
RDRiccardo Deidda
Riccardo Deidda
FCFlorentin Coppey
Florentin Coppey
DDDhouha Damergi
Dhouha Damergi
CSCédric Schelling
Cédric Schelling
LCLaureen Coïc
Laureen Coïc
Eric ZiemonsEric Ziemons
Eric Ziemons

1 May 2015 in International Journal of Pharmaceutics
Verified
Journal Article
Closed access
PCPierre-François Chavez
Pierre-François Chavez
PLPierre Lebrun
Pierre Lebrun
PSPierre-Yves Sacré
Pierre-Yves Sacré
CBCharlotte De Bleye
Charlotte De Bleye
LNLauranne Netchacovitch
Lauranne Netchacovitch
EZEric Ziemons
Eric Ziemons

1 February 2023 in The American Journal of Tropical Medicine and Hygiene
Verified
Journal Article
Closed access
PDF file
CTChristelle Ange Waffo Tchounga
Christelle Ange Waffo Tchounga
PSPierre-Yves Sacré
Pierre-Yves Sacré
PHPatient Ciza Hamuli
Patient Ciza Hamuli
RMRose Ngono Mballa
Rose Ngono Mballa
CBCharlotte De Bleye
Charlotte De Bleye
RDRoland MARINI DJANG'EING'A
Roland MARINI DJANG'EING'A
: Quality is one of the essential components of medicines and needs to be ensured to preserve the population’s health. This can be achieved through post-marketing quality control of medicines and is one of the most important duties of national regulatory authorities. In collaboration with the Cameroonian National Drug Quality Control and Valuation Laboratory, the decision was made to initiate a prevalence study to assess the quality of antiinfective medicines in Cameroon. A total of 150 samples of ciprofloxacin tablets and 142 samples of metronidazole tablets were collected from 76 licensed pharmacies and 75 informal vendors in three cities in Cameroon using a random strategy wherever possible and a mystery shopper approach. Three tests were carried out on each of the samples. Visual inspection allowed to find two falsified samples (0.7%) due to lack of information about the manufacturing company, and five more samples (1.7%) were deemed to be substandard due to flaws in the product. An additional 13 samples (4.5%) failed disintegration testing, and six (2.1%) others failed high-performance liquid chromatography assay testing due to insufficient active pharmaceutical ingredient (API) content. All samples were found to contain some API. A prevalence of 7.9% substandard or falsified (SF) medicines was found. Moreover, the prevalence of outlets selling SF medicines was greater in the informal sector (26.7%) than in the formal sector (2.6%). Although the prevalence of SF medicines found was low, efforts need to be made by national regulatory authorities to monitor the pharmaceutical market more closely.

1 July 2020 in Journal of Pharmaceutical and Biomedical Analysis
Verified
Journal Article
Closed access
CBCharlotte De Bleye
Charlotte De Bleye
MFM. Fontaine
M. Fontaine
EDE. Dumont
E. Dumont
PSP.-Y. Sacré
P.-Y. Sacré
PHPh. Hubert
Ph. Hubert
EZE. Ziemons
E. Ziemons

1 January 2010 in Talanta
Verified
Journal Article
Closed access
CHCédric Hubert
Cédric Hubert
Eric ZiemonsEric Ziemons
Eric Ziemons
ERE. Rozet
E. Rozet
ABA. Breuer
A. Breuer
ALA. Lambert
A. Lambert
PHPh. Hubert
Ph. Hubert

22 July 2024 in Molecules
Verified
Journal Article
Open access
PDF file
JHJulie Horne
Julie Horne
PBPierre Beckers
Pierre Beckers
PSPierre-Yves Sacré
Pierre-Yves Sacré
CBCharlotte De Bleye
Charlotte De Bleye
PFPierre Francotte
Pierre Francotte
CHCédric Hubert
Cédric Hubert
A major limitation preventing the use of surface-enhanced Raman scattering (SERS) in routine analyses is the signal variability due to the heterogeneity of metallic nanoparticles used as SERS substrates. This study aimed to robustly optimise a synthesis process of silver nanoparticles to improve the measured SERS signal repeatability and the protocol synthesis repeatability. The process is inspired by a chemical reduction method associated with microwave irradiation to guarantee better controlled and uniform heating. The innovative Quality by Design strategy was implemented to optimise the different parameters of the process. A preliminary investigation design was firstly carried out to evaluate the influence of four parameters selected by means of an Ishikawa diagram. The critical quality attributes were to maximise the intensity of the SERS response and minimise its variance. The reaction time, temperature and stirring speed are critical process parameters. These were optimised using an I-optimal design. A robust operating zone covering the optimal reaction conditions (3.36 min–130 °C–600 rpm) associated with a probability of success was modelled. Validation of this point confirmed the prediction with intra- and inter-batch variabilities of less than 15%. In conclusion, this study successfully optimised silver nanoparticles by a rapid, low cost and simple technique enhancing the quantitative perspectives of SERS.